1.27 N/A 0.58% 0.00% Distribution costs (41.75 ) (24.14 ) (17.61 ) 72.95% (19.11%) (13.74%) Administrative expenses (95.74 ) (94.34 ) (1.40 ) 1.48% (43.82%) (53.71%) Other Expenses Impairment loss of
-27.5% -24.5% 2,120.4 1,782.4 -15.9% Other income 31.8 15.9 22.9 -28.1% +44.1% 51.7 38.7 -25.1% Selling and distribution expenses 587.2 536.7 463.7 -21.0% -13.6% 1,175.1 1,000.4 -14.9% Administrative
) % Revenue from sales and service 1,788.5 2,025.3 1,187.1 (236.8) (11.7) 601.4 50.7 Cost of sales and service 1,499.5 1,686.8 998.7 (187.3) (11.1) 500.8 50.1 Selling and distribution expenses 73.7 78.7 52.0
sales staffs, advertising media fee for product promotion, distribution fee paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of company’ s products in the
0.00 12.21 N/A 6.95% 0.00% Revenues from reduction of defaulted interest under the Court’s order 16.66 0.00 16.66 N/A 9.48% 0.00% Distribution costs (24.14 ) (26.13 ) (1.99 ) 7.62% (13.74%) (8.83
increase of depreciation cost from expanding Boonterm kiosk. 2) Sales profit was Bt0.43mn, a decrease from 1Q2017 which was Bt1.44mn, represented 70.1%. In 1Q18, the Company emphasize efficient Boonterm
assets of Bt3,852.52mn, decreasing 1.6% compared to total assets last year, mainly due to emphasizing in efficient Boonterm kiosk location strategy in 2018 rather than emphasizing on expanding the kiosks
trustee, under Clause 20; (13) the trust’s disclosure of information, under Clause 21; (14) the distribution to the unit holders, under Clause 22; (15) the proposal for resolution and the general meeting of
from increasing of loans for expanding Boonterm Kiosk Interest-bearing debt to Equity ratio increased to 1.00, mainly from loans for investment and working capital. Return on Asset stood at 18.0%, mainly